论文部分内容阅读
目的:对参七黄复方中的抗癌活性组分芦荟大黄素、大黄素、大黄酸、人参皂苷Rh2、槐定碱、苦参碱配伍后进行抗结肠癌的体外筛选实验,以优选最佳组分配伍。方法:采用均匀设计法设计各组分的配伍剂量,应用MTT法测定各配方对SW620细胞株增殖活性的影响,应用光学显微镜、荧光显微镜进行细胞形态学观察。结果:优选出的最佳组分配方为大黄素100μg/m L、槐定碱2000μg/m L、苦参碱2500μg/m L,对SW620结肠癌细胞抑制率达95.4%。结论:此组分配方可对结肠腺癌细胞株SW620的增殖显著抑制并诱导细胞凋亡,为进一步研发治疗结肠癌的靶向新药提供实验依据。
OBJECTIVE: To screen the antitumor active ingredient aloe-emodin, emodin, rhein, ginsenoside Rh2, sophoridine and matrine in Shenqihuang Compound for anti-colon cancer screening in vitro, Component compatibility. Methods: The uniform dose of each component was designed by uniform design. The effects of different formulations on the proliferation of SW620 cell line were determined by MTT assay. The morphological changes of SW620 cells were observed by light microscope and fluorescence microscope. Results: The optimal formulation was 100μg / m L of emodin, 2000μg / m L of sophoridine and 2500μg / m L of matrine. The inhibition rate to SW620 colon cancer cells was 95.4%. Conclusion: The formula can significantly inhibit the proliferation of colon adenocarcinoma cell line SW620 and induce apoptosis, providing experimental basis for further research and development of targeted drugs for the treatment of colon cancer.